Table 3.

Patient-specific disease characteristics, treatment, and outcome

Lymphoma typeAnn Arbor stageLymphoma EBV/KSHV statusBaseline CD4, cells/μLBaseline HIV, copies/mLBortezomib dose cohort, mg/m2Total no. of cycles completedBest responseDuration of response, wkPostprotocol lymphoma therapySurvival, wk
DLBCLIVEBV positive294241 4900.76CR>68.5None>68
DLBCLIVEBV positive7785 1220.72PD*NARadiation38
DLBCLIVEBV positive4021700.74CR*>55None>55
PlasmablasticIVEBV positive1691260.72SDNAAHSCT29
PELIVEBV and KSHV positive570480.74PR15AHSCT24
DLBCLIIEBV positive2610.72PDNARadiation26
DLBCLIVEBV positive336Undetectable1.03PR*4Not reported19
Not reported1.00NANANANA
DLBCLIVEBV positive4880001.0<2NENENot reported9
DLBCLIVEBV positive45891.0<1NENENone3
HodgkinIIIEBV positive283<4001.02CR*>55AHSCT>55
PlasmablasticIEBV positive476<201.04CR*>59AHSCT>59
DLBCLIIEEBV positive435Undetectable1.03PR>40AHSCT>40
DLBCLIVEBV negative3344.41.03PR*6Not reported>13
HodgkinIIIEBV positive3560.71.33PR>60AHSCT>60
PELIIEBV and KSHV positive4501.21.36CR*>58None>58
DLBCLIIIEBV negative2370.41.33PR>55AHSCT>55
PlasmablasticIEBV positive2940.451.54PR5Not reported>14
DLBCLIVEBV negative29624 8171.53CR*>43None52
DLBCLIVEBV positive401241.55PR*>65Radiation>65
DLBCLIUnknown2414.21.53PR2Not reported>12
DLBCLIIUnknown7731.31.54PR*>52R2-GemOx + AHSCT>52
DLBCLIVEBV negative339Undetectable1.53CR*6AHSCT16
  • NA, not applicable; NE, not evaluable; PD, progressive disease; R2-GemOx, lenalidomide, rituximab, gemcitabine, and oxaliplatin; SD, stable disease.

  • * PET imaging used in response assessment.

  • In continued CR at time of death attributed to complications of AHSCT.